Boehringer Ingelheim （Canada）

Since Boehringer Ingelheim (Canada) arrived in Canada in 1972, the company has played various indispensable roles in the health of Canadians. Committed to finding medical breakthroughs and investing in research, development, and healthcare to meet unmet medical needs. By participating in medical and pharmaceutical research in Canada and globally, it has contributed to significant improvements in healthcare and developed innovative and cost-effective drugs. It has gained a reputation in treating respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), and expanded its scope of work to include diseases such as hypertension, stroke, arthritis, benign prostatic hyperplasia (BPH), Parkinson's disease, and HIV/AIDS.